What is Esperion Therapeutics's cost not yet recognized?

Esperion Therapeutics (ESPR) reported cost not yet recognized of $4.8M in Q4 2025.

How has Esperion Therapeutics's cost not yet recognized changed year-over-year?

Esperion Therapeutics's cost not yet recognized decreased by 0.0% year-over-year, from $4.8M to $4.8M.

What is the long-term trend for Esperion Therapeutics's cost not yet recognized?

Over 5 years (2020 to 2025), Esperion Therapeutics's cost not yet recognized has grown at a -29.1% compound annual growth rate (CAGR), from $26.8M to $4.8M.

Esperion Therapeutics ESPR Cost not yet recognized

Cost not yet recognized at other companies

Nurix Therapeutics, Inc.NRIX

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's cost not yet recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's cost not yet recognized?: Esperion Therapeutics (ESPR) reported cost not yet recognized of $4.8M in Q4 2025.
How has Esperion Therapeutics's cost not yet recognized changed year-over-year?: Esperion Therapeutics's cost not yet recognized decreased by 0.0% year-over-year, from $4.8M to $4.8M.
What is the long-term trend for Esperion Therapeutics's cost not yet recognized?: Over 5 years (2020 to 2025), Esperion Therapeutics's cost not yet recognized has grown at a -29.1% compound annual growth rate (CAGR), from $26.8M to $4.8M.